^
Association details:
| Biomarker: | ADAM9 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | izeltabart tapatansine (IMGC936) (Microtubule inhibitor, ADAM9-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Estudio del medicamento IMGC936 (primera vez que se prueba en personas) en pacientes con tumores sólidos avanzados
Excerpt:
...Tumor specimens for retrospective determination of ADAM9 expression via IHC staining will be collected from all participants and will be assayed at a central laboratory designated by the sponsor.6. ...
Trial ID:
Source:
Title:
Abstract 1533: IMGC936, a first-in-class ADAM9-targeting antibody-drug conjugate, demonstrates promising anti-tumor activity
Published date:
07/05/2022
Excerpt:
In vitro studies demonstrated targeted cytotoxicity of IMGC936 across a panel of ADAM9-positve tumor cell lines with activity at least 2 logs greater than a non-targeting conjugate. Consistent with the in vitroactivity, an anti-ADAM9-DM21 conjugate displayed compelling anti-tumor activity in multiple xenograft models representing non-small cell lung, gastric and colorectal cancers....Based on the totality of the preclinical data, IMGC936 represents a promising therapeutic candidate to target a wide range of ADAM9-expressing tumors.
DOI:
https://doi.org/10.1158/1538-7445.AM2019-1533
